SCHEMBL4395632

SCHEMBL4395632

CCOc1cc(OC)cc(CC(=O)O)c1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.51
KDM4E B2RXH2 4/20 0.48
ABL1 P00519 1/20 0.48
POLB P06746 1/20 0.48
MAPT P10636 1/20 0.48
RECQL P46063 1/20 0.48
RIN1 Q13671 1/20 0.48
CTDSP1 Q9GZU7 1/20 0.48
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
TSHR P16473 1/20 0.40
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
RXRG P48443 1/20 0.39
AKR1C3 P42330 2/20 0.38
THRB P10828 1/20 0.38
PTGS1 P23219 1/20 0.38
AKR1C2 P52895 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4407638 0.91 HSD17B10 (0.43) HSD17B10KDM4EABL1POLBMAPT
SCHEMBL4404615 0.88 HSD17B10 (0.51) HSD17B10KDM4EABL1POLBMAPT
SCHEMBL4395434 0.88 HSD17B10 (0.61) HSD17B10KDM4EABL1POLBMAPT
SCHEMBL4405629 0.82 POLB (0.44) HSD17B10KDM4EABL1POLBMAPT
SCHEMBL4398320 0.81 ABL1 (0.39) KDM4EABL1MTNR1AMTNR1BTSHR
SCHEMBL23229043 0.79 HSD17B10 (0.62) HSD17B10KDM4EPOLBMAPTMTNR1A
SCHEMBL17967503 0.79 HSD17B10 (0.77) HSD17B10KDM4EABL1POLBMAPT
SCHEMBL4412474 0.79 TSHR (0.47) HSD17B10KDM4EPOLBMAPTTSHR
SCHEMBL4405608 0.78 POLB (0.65) HSD17B10KDM4EABL1POLBMAPT
SCHEMBL4405835 0.77 TSHR (0.46) HSD17B10KDM4EMAPTTSHRRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 US disclosed
EP-1549651-A1 KINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-07-06 EP disclosed
WO-2004011465-A1 KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-05 WO disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 HSD17B10 2499/4885KDM4E 954/4885ABL1 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.